Session Details

W002 Hands-on: Patch Testing Workshop

Mon, Mar 11, 9:00 AM - 12:00 PM
Room 9
3 CME Available Workshop CCP Ticketed
View Map

DESCRIPTION

Tuition fee and ticket required for admission

This hands on session will teach attendees how to recognize and diagnose allergic contact dermatitis using epicutaneous patch testing. Patterns of allergic contact dermatitis will be discussed and possible culprit allergens identified. Live demonstration in small group sessions will be performed. Information on additional patch testing resources and billing will be reviewed. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.

LEARNING OBJECTIVES

1.

Assess patients for allergic contact dermatitis through history taking and physical examination.

2.

Diagnose and identify allergic contact dermatitis through application of epicutaneous patch testing.

3.

Recognize and determine relevant positive patch test reactions through hands on training.

SCHEDULE

4:00 PM

Overview of ACD and Patch Testing

Ari M Goldminz, MD, FAAD

4:20 PM

What Your Need for Patch Testing

Wei-Che Ko, MD, FAAD

4:40 PM

Practicum (Loading Chambers and Patch Placement)

5:05 PM

Patient Interview

Alina Goldenberg, MD, FAAD

5:30 PM

Reading Patch Test Reactions

Wei-Che Ko, MD, FAAD

5:45 PM

Interpreting Patch Test Reactions

Ari M Goldminz, MD, FAAD

6:05 PM

Practicum (Patch Test Reading)

6:25 PM

Patch Test Resources and Billing

Alina Goldenberg, MD, FAAD

6:45 PM

Q&A

SPEAKERS

Alina Goldenberg, MD, FAAD

Alina Goldenberg, MD, FAAD

Ari M Goldminz, MD, FAAD

Ari M Goldminz, MD, FAAD

Wei-Che Ko, MD, FAAD

Wei-Che Ko, MD, FAAD

SPEAKER DISCLOSURES

Alina Goldenberg, MD, FAAD

No financial relationships exist with ineligible companies.

Ari M Goldminz, MD, FAAD

Johnson and Johnson – Stockholder(Stock); Regeneron – Investigator(Grants/Research Funding);

Wei-Che Ko, MD, FAAD

No financial relationships exist with ineligible companies.